Figure 3.

Effects of VEGF-mediated SFK activation on CRC migration. HT29 and KM12L4 CRC cells were pretreated with IMC-18F1 (20 μg ml⁻¹), the novel, potent Src kinase inhibitor, AP23464 (1 μM), a commercially available Src inhibitor, PP2 (10 μM) or PBS control for 1 h and allowed to migrate in a modified Boyden chamber containing VEGF-A (10 ng ml⁻¹) or 10% FBS for 72 h. (A, B) Representative photos of migrated cells ( × 100 magnification). (C, D) Quantitation of migrated cells. ^*P<0.001 vs control cells. ^**P<0.001 vs cells treated with VEGF alone. Bars represent s.e.m.